TEVA PHARMACEUTICAL INDUSTRIES LIMITED Deferred Foreign Income Tax Expense (Benefit)
TEVA PHARMACEUTICAL INDUSTRIES LIMITED (TEVJF) reported Deferred Foreign Income Tax Expense (Benefit) of -$868.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-03.
Financial Statements › Expense Statement › Income Tax
us-gaap:DeferredForeignIncomeTaxExpenseBenefit · last filed 2026-02-03
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED deferred foreign income tax expense (benefit) for fiscal 2025 was -$868.00M.
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED deferred foreign income tax expense (benefit) for fiscal 2024 was -$484.00M, a 593.88% decline from fiscal 2023.
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED deferred foreign income tax expense (benefit) for fiscal 2023 was $98.00M.
| Period end | Deferred Foreign Income Tax Expense (Benefit) 12 month |
|---|---|
| 2025-12-31 | -$868.00M 10-K · filed 2026-02-03 |
| 2024-12-31 | -$484.00M 10-K · filed 2026-02-03 |
| 2023-12-31 | $98.00M 10-K · filed 2026-02-03 |